Treatment of One Case with Cryoglobulinaemia Secondary to Connective Tissue Disease with Small Doses of Rituximab.

Abstract

OBJECTIVE:

This study aims to observe the clinical efficacy of low-dose rituximab in patients with cryoglobulinaemia secondary to connective tissue diseases.

METHODS:

Rituximab (100 mg) was infused in patients once a week for four weeks, combined with prednisone (20 mg) once a day, and reduced regularly. Treatment effect was observed regularly.

RESULTS:

Joint pain, fever, rash and fatigue symptoms in patients eased. The serology (globulin, erythrocyte sedimentation rate, C-reactive protein, lactate dehydrogenase and others) parameters returned to normal.

CONCLUSION:

Low-dose rituximab therapy for cryoglobulinaemia secondary to connective tissue diseases was safe and effective, and can be used as a treatment option in this condition.

• Authors: X Wang, Y Ning, L Wang, J Zhang, Y Wang, H Shen
• Journal: The West Indian medical journal (West Indian Med J) Vol. 65 Issue 2 Pg. 398-400 (Apr 04 2016) ISSN: 0043-3144 [Print] Jamaica
• PMID: 28358454 (Publication Type: Journal Article)